In many countries, patients with a bleeding disorder only have access to factor through donations. The World Federation of Hemophilia (WFH) Humanitarian Aid Program is the primary donor of factor around the world, helping thousands of people to live more normal lives every year. By providing patients with a predictable and sustainable flow of hemophilia treatment products, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care.
Two prestigious publications recognized the efforts of the WFH Humanitarian Aid Program in 2020. In Bleeding disorders: making strides towards treatment for all, published in The Lancet Haematology, the Program as well as other important efforts being led by the WFH were praised. In the article, Arthroplasty in haemophilia: Double‐edged sword in low/middle‐income countries (B. Poudyal et al)—seen in Haemophilia, a Wiley publication and the official journal of the WFH—Humanitarian Aid Program efforts in Nepal were recognized.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer, our Visionary Contributor; Grifols and Roche, our Leadership Contributors; and our Contributor, CSL Behring. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.